Discover FiteBac®

The Future of Regenerative Medicine & Pharmaceuticals

 K21 promotes wound healing. Antimicrobial quaternary ammonium silane K21 is a safe and affordable novel compound for use in advanced wound care.

Potential effects of K21 in chronic wound healing process in a pre-clinical model.
View PDF Report

K21 Molecule – Images & Video

Hard-to-heal wounds are one of the major complications associated with diabetes, leading to limb amputation, disability and even death. There is an urgent need for novel therapeutics that are both effective and inexpensive for patients with diabetes who have hard-to-heal wounds.

K21 is a quaternary ammonium silane molecule that exhibits bactericidal, viricidal and fungicidal activity, with less toxicity and greater efficacy compared with other antiseptics such as chlorhexidine and benzalkonium chloride or antimicrobial silver. Biofilm colonization is also inhibited.

As an advanced wound care product, a novel nontoxic antiseptic with immunomodulatory activity would be hugely beneficial for such patients. K21 is one such novel antiseptic.


Composition of matter patents maintained in U.S., Europe, China

U.S. patents granted – silsesquioxanes, elastomers, drug

Trademarks received U.S., Europe, China, India, and Brazil


FDA recognition of NME
(new molecular entity)

FDA Master file K21 QAS 

FDA NDA 128706 K21 QAS Topical Antimicrobial

FDA Cleared Medical Devices

FiteBac Antimicrobial Cavity Cleanser

FiteBac Cc Orthoseal